Veradermics (MANE) Treasury Shares (2024 - 2025)
Veradermics (MANE) posted Treasury Shares of $118.7 million for Q4 2025, up 822.5% on a QoQ basis from $12.9 million in Q1 2025, and up 114.82% year-over-year from $55.2 million in Q4 2024.
Veradermics (MANE) Treasury Shares (2024 - 2025) Analysis & Trends
Veradermics' Treasury Shares history runs 2 years deep, the most recent figure standing at $118.7 million for Q4 2025.
- Quarterly Treasury Shares rose 114.82% year-over-year to $118.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $118.7 million (up 114.82% YoY) and the FY2025 annual result came in at $118.7 million, up 114.82% from the prior year.
- Treasury Shares was $118.7 million for Q4 2025 at Veradermics, up from $12.9 million in the prior quarter.
- Across five years, Treasury Shares topped out at $118.7 million in Q4 2025 and bottomed at $12.9 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Treasury Shares (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -21,709.08 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 265,401.92 |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 19.41 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 5.14 Mn |
| 10 | Veradermics | 2.63 Bn | 2.63 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 118.68 Mn |
| Dec 31, 2025 | 118.68 Mn |
| Mar 31, 2025 | 12.87 Mn |
| Mar 31, 2025 | 12.87 Mn |
| Dec 31, 2024 | 55.25 Mn |
| Dec 31, 2024 | 55.25 Mn |